Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 9/20 | 0.66 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.54 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.54 |
| ▸ | GRIA1 | P42261 | 7/20 | 0.48 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.48 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.48 |
| ▸ | PKN2 | Q16513 | 2/20 | 0.48 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CACNG2 | Q9Y698 | 1/20 | 0.47 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.44 |
| ▸ | PRKCH | P24723 | 1/20 | 0.44 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.44 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22085801 | 0.84 | MTOR (0.56) | PIK3CAPIK3CDPIK3CGROCK2TGFBR1 | |
| SCHEMBL22087432 | 0.83 | PIK3CA (0.46) | PIK3CAPIK3CDPIK3CGROCK2ROCK1 | |
| SCHEMBL22087294 | 0.83 | PIK3CA (0.46) | PIK3CAPIK3CDPIK3CGROCK2ROCK1 | |
| SCHEMBL22085807 | 0.83 | PIK3CA (0.46) | PIK3CAPIK3CDPIK3CGROCK2ROCK1 | |
| SCHEMBL22087274 | 0.79 | PIK3CA (1.00) | PIK3CAPIK3CDPIK3CG | |
| SCHEMBL22085155 | 0.78 | PIK3CA (0.72) | PIK3CAMAP4K4 | |
| SCHEMBL22085148 | 0.78 | PIK3CA (0.74) | PIK3CAMAP4K4 | |
| SCHEMBL16727862 | 0.78 | PIK3CA (0.75) | PIK3CAPIK3CDMAP4K4 | |
| SCHEMBL22085248 | 0.78 | PIK3CA (0.62) | PIK3CAPIK3CDPIK3CGGRIA1MAP4K4 | |
| SCHEMBL22085160 | 0.76 | PIK3CA (0.69) | PIK3CAPIK3CDPIK3CGMAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3475285-B1 | MECHANISTIC TARGET OF RAPAMYCIN SIGNALING PATHWAY INHIBITORS AND THERAPEUTIC APPLICATIONS THEREOF | SUZHOU KINTOR PHARMACEUTICALS INC (CN) | 2022-02-09 | — | — | EP | disclosed |
| US-11242346-B2 | Mechanistic target of rapamycin signaling pathway inhibitors and therapeutic applications thereof | SUZHOU KINTOR PHARMACEUTICALS, INC. (CN) | 2022-02-08 | — | — | US | disclosed |
| US-20200181147-A1 | MECHANISTIC TARGET OF RAPAMYCIN SIGNALING PATHWAY INHIBITORS AND THERAPEUTIC APPLICATIONS THEREOF | SUZHOU KINTOR PHARMACEUTICALS, INC. (CN) | 2020-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11242346-B2 | Mechanistic target of rapamycin signaling pathway inhibitors and therapeutic applications thereof | MTOR, RPTOR, RICTOR | PIK3CA 20/4885PIK3CD 27/4885PIK3CG 51/4885 |
| US-20200181147-A1 | MECHANISTIC TARGET OF RAPAMYCIN SIGNALING PATHWAY INHIBITORS AND THERAPEUTIC APPLICATIONS THEREOF | MTOR, RPTOR, RICTOR | PIK3CA 20/4885PIK3CD 27/4885PIK3CG 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.